Racura Oncology Ltd (ASX:RAC)
2.300
+0.010 (0.44%)
At close: Feb 5, 2026
Racura Oncology Revenue
In the fiscal year ending June 30, 2025, Racura Oncology had annual revenue of 6.04M AUD with 24.96% growth. Racura Oncology had revenue of 788.42K in the half year ending June 30, 2025, a decrease of -56.50%.
Revenue
6.04M
Revenue Growth
+24.96%
P/S Ratio
69.09
Revenue / Employee
n/a
Employees
n/a
Market Cap
417.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 6.04M | 1.21M | 24.96% |
| Jun 30, 2024 | 4.84M | 1.70M | 54.29% |
| Jun 30, 2023 | 3.13M | 2.43M | 342.83% |
| Jun 30, 2022 | 707.81K | 320.42K | 82.71% |
| Jun 30, 2021 | 387.39K | 228.01K | 143.07% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 95.02M |
| PYC Therapeutics | 23.49M |
| Orthocell | 7.55M |
| Recce Pharmaceuticals | 7.51M |
| Starpharma Holdings | 5.85M |
| Botanix Pharmaceuticals | 5.79M |
| Dimerix | 5.59M |
| Actinogen Medical | 5.49M |